Throughout the last three months, 6 analysts have evaluated Corteva CTVA, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 2 | 1 | 0 | 0 |
Last 30D | 0 | 1 | 1 | 0 | 0 |
1M Ago | 3 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 1 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Corteva, presenting an average target of $67.17, a high estimate of $71.00, and a low estimate of $62.00. This upward trend is apparent, with the current average reflecting a 5.61% increase from the previous average price target of $63.60.
Breaking Down Analyst Ratings: A Detailed Examination
In examining recent analyst actions, we gain insights into how financial experts perceive Corteva. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Benjamin Theurer | Barclays | Raises | Equal-Weight | $62.00 | $58.00 |
Kristen Owen | Oppenheimer | Raises | Outperform | $70.00 | $69.00 |
Joshua Spector | UBS | Raises | Buy | $71.00 | $67.00 |
Patrick Cunningham | Citigroup | Announces | Buy | $68.00 | - |
Steve Byrne | B of A Securities | Raises | Buy | $67.00 | $59.00 |
Vincent Andrews | Morgan Stanley | Maintains | Overweight | $65.00 | $65.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Corteva. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Corteva compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Corteva's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Corteva's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Corteva analyst ratings.
Get to Know Corteva Better
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
Key Indicators: Corteva's Financial Health
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Corteva's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -61.94%. This indicates a decrease in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Corteva's net margin excels beyond industry benchmarks, reaching -22.53%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Corteva's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.1%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Corteva's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.26% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Corteva's debt-to-equity ratio is below the industry average at 0.23, reflecting a lower dependency on debt financing and a more conservative financial approach.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.